The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats

Purnomo, Hery D. and Kusuma, Refani A. and Sianturi, Elfrida and Haroen, Ryan F. and Solichin, Muchamad R. and Nissa, Choirun and Pramono, Adriyan and Mahati, Endang and Noer, Etika R. (2023) The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats. Journal of Nutrition and Metabolism, 2023: 2313503. ISSN 20900724

[thumbnail of The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats.pdf] Text
The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats.pdf - Published Version
Restricted to Registered users only
Available under License Creative Commons Attribution.

Download (1MB) | Request a copy

Abstract

Liver damage characterized by fibrosis and necrosis can worsen the condition of liver disease. Liver disease is associated with impaired immune response and may affect short-chain fatty acid (SCFA) gut metabolites. Hepatogomax enteral formula was developed, which contains brain-chain amino acids (BCAAs) and middle-chain triglycerides (MCTs), which could repair liver tissue damage, improve the inflammatory status, and modulate SCFA in liver damage. The study aimed to determine the effect of hepatogomax on liver tissue repair, inflammation (TNF-α and IL-6), and SCFA levels in thioacetamide (TAA)-induced rats. The induction of TAA causes liver steatosis, increasing TNF-α and IL-6, and decreasing SCFA levels. Hepatogomax at a dose of 14.6 g/200 gBW significantly reduces TNF-α and IL-6 levels and increases SCFA levels (p < 0.05). The number of steatosis between groups P2 and P3 was lower as compared to a group of negative control K2 (p < 0.05). Hepatogomax, in a dose-dependent manner, may repair liver tissue and improve inflammatory response and SCFA levels in TAA-induced rats.

Item Type: Article
Additional Information: Library Dosen
Uncontrolled Keywords: hepatogomax enteral formula; interleukin 6; liver protective agent; short chain fatty acid; thioacetamide; tumor necrosis factor; unclassified drug, adult; animal experiment; animal model; animal tissue; Article; body weight; controlled study; fatty liver; hepatitis; histopathology; liver tissue; male; nonhuman; rat
Subjects: R Medicine > RZ Other systems of medicine
Divisions: Faculty of Medicine, Public Health and Nursing > Biomedical Sciences
Depositing User: Ani PURWANDARI
Date Deposited: 03 Jul 2024 06:30
Last Modified: 03 Jul 2024 06:30
URI: https://ir.lib.ugm.ac.id/id/eprint/2642

Actions (login required)

View Item
View Item